AwardTape · Defense awards · Primmune Therapeutics, Inc
Primmune Therapeutics, Inc: $11.2M in DoD and DHS awards
Primmune Therapeutics, Inc holds 1 DoD and DHS prime award with $11.2M obligated Jan 30, 2024 to Apr 20, 2026. Largest category: Defense systems R&D at $11.2M; largest buyer: Defense Threat Reduction Agency at $11.2M.
| Obligated FY2024+ | $11.2M |
|---|---|
| Awards | 1 |
| FY2024 | $7.8M |
| FY2025 | $2.8M |
| FY2026 to date | $584K |
| Lifetime obligated on these awards | $11.3M |
| Parent company (as reported) | Primmune Therapeutics, Inc |
| First and latest action | Jan 30, 2024 · Apr 20, 2026 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense systems R&D | $11.2M | 1 awards | 100% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense Threat Reduction Agency | $11.2M | 1 awards | 100% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| HDTRA124C0014 definitive contract | $11.2M | Oral broad spectrum antiviral tlr7 agonist for treatment of lassa fever | Defense Threat Reduction Agency | Defense systems R&D | Apr 20, 2026 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial